Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
APLT logo

Applied Therapeutics Inc (APLT)APLT

Upturn stock ratingUpturn stock rating
Applied Therapeutics Inc
$9.26
Delayed price
Profit since last BUY6.19%
Consider higher Upturn Star rating
upturn advisory
BUY since 10 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/04/2024: APLT (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -59.45%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 26
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/04/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -59.45%
Avg. Invested days: 26
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/04/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.04B USD
Price to earnings Ratio -
1Y Target Price 12.8
Dividends yield (FY) -
Basic EPS (TTM) -1.43
Volume (30-day avg) 1836309
Beta 2.04
52 Weeks Range 1.79 - 9.51
Updated Date 11/3/2024
Company Size Small-Cap Stock
Market Capitalization 1.04B USD
Price to earnings Ratio -
1Y Target Price 12.8
Dividends yield (FY) -
Basic EPS (TTM) -1.43
Volume (30-day avg) 1836309
Beta 2.04
52 Weeks Range 1.79 - 9.51
Updated Date 11/3/2024

Earnings Date

Report Date 2024-11-07
When BeforeMarket
Estimate -0.16
Actual -
Report Date 2024-11-07
When BeforeMarket
Estimate -0.16
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -14194.44%

Management Effectiveness

Return on Assets (TTM) -56.9%
Return on Equity (TTM) -473.39%

Revenue by Products

Valuation

Trailing PE -
Forward PE -
Enterprise Value 921970603
Price to Sales(TTM) 54.68
Enterprise Value to Revenue 62.37
Enterprise Value to EBITDA -9.71
Shares Outstanding 114846000
Shares Floating 83260101
Percent Insiders 5.31
Percent Institutions 92.76
Trailing PE -
Forward PE -
Enterprise Value 921970603
Price to Sales(TTM) 54.68
Enterprise Value to Revenue 62.37
Enterprise Value to EBITDA -9.71
Shares Outstanding 114846000
Shares Floating 83260101
Percent Insiders 5.31
Percent Institutions 92.76

Analyst Ratings

Rating 4.83
Target Price 7.67
Buy 1
Strong Buy 5
Hold -
Sell -
Strong Sell -
Rating 4.83
Target Price 7.67
Buy 1
Strong Buy 5
Hold -
Sell -
Strong Sell -

AI Summarization

Applied Therapeutics, Inc.: A Comprehensive Overview

Company Profile:

Detailed history and background of Applied Therapeutics Inc.:

Applied Therapeutics, Inc. (APLT) is a clinical-stage biopharmaceutical company established in 2012 and headquartered in New York City. APLT focuses on developing novel gene therapy and cell therapy products for rare diseases with significant unmet medical needs.

Description of the company’s core business areas:

APLT's primary focus is on:

  • Gene therapy: Developing adeno-associated virus (AAV)-based gene therapy platforms for neurodegenerative and cardiovascular diseases.
  • Cell therapy: Researching and developing cell therapy solutions for the treatment of autoimmune and inflammatory diseases.
  • Clinical research: Conducting Phase 1/2 clinical trials for its lead gene therapy candidates, AT-007 and AT-008, targeting Dravet syndrome and transthyretin-mediated amyloidosis (ATTRv-PN), respectively.

Overview of the company’s leadership team and corporate structure:

  • Sheng Li, Ph.D.: Chairman and CEO, with extensive experience in drug development and business leadership.
  • James Hickling: Chief Scientific Officer, with expertise in gene therapy and cell therapy.
  • Richard Pascoe: Chief Financial Officer, brings over 20 years of financial leadership experience.
  • Board of Directors: Comprises experienced professionals with expertise in the life sciences and finance sectors.

Top Products and Market Share:

Identification and description of Applied Therapeutics Inc's top products and offerings:

  • AT-007: An AAV-based gene therapy candidate for the treatment of Dravet syndrome, a rare and severe form of epilepsy.
  • AT-008: An AAV-based gene therapy candidate for the treatment of ATTRv-PN, a debilitating form of amyloidosis.

Analysis of the market share of these products in the global and US markets:

Neither AT-007 nor AT-008 are currently available commercially, limiting their market share analysis. However, they hold the potential to become significant players within their respective markets.

  • Dravet syndrome: The global market for Dravet syndrome treatments is estimated to reach $750 million by 2027.
  • ATTRv-PN: The global market for ATTRv-PN treatments is expected to reach $3.5 billion by 2027.

Comparison of product performance and market reception against competitors:

Both AT-007 and AT-008 are in the early stages of development, and their efficacy and safety profiles haven't been completely established. Therefore, their performance and market reception compared to competitors require further clinical data and market authorization.

Total Addressable Market:

  • Dravet syndrome: Approximately 60,000 individuals worldwide, with a significant orphan drug market potential.
  • ATTRv-PN: An estimated 50,000 individuals worldwide, presenting a substantial market opportunity.

Financial Performance:

Detailed analysis of recent financial statements:

  • Revenue: APLT currently generates no product revenue but relies on research and development grants, collaboration agreements, and licensing fees.
  • Net income: APLT is a pre-revenue company and has consistently reported net losses due to research and development expenses.
  • Profit margins: As a development-stage company, APLT does not have meaningful profit margins.
  • Earnings per share (EPS): APLT has not recorded any EPS due to its consistent net losses.

Year-over-year financial performance comparison:

Financial performance analysis requires comparing data from multiple years, considering APLT is in the early development stage.

Examination of cash flow statements and balance sheet health:

  • Cash flow: APLT primarily relies on external financing to fund its operations.
  • Balance sheet: The company holds a moderate amount of cash and equivalents to support its ongoing research and development activities.

Dividends and Shareholder Returns:

Dividend History: APLT does not currently distribute dividends due to its pre-revenue status and focus on reinvesting resources in research and development.

Shareholder Returns: APLT's stock price has experienced volatility due to its clinical development stage and dependence on research progress. Analyzing historical shareholder returns requires considering the time period and investment strategy.

Growth Trajectory:

Historical growth analysis:

APLT's historical growth analysis is limited due to its recent establishment and focus on early-stage development.

Future growth projections:

Future growth depends on the successful completion of clinical trials, regulatory approvals, and potential commercialization of its lead candidates. Favorable clinical trial results and market acceptance of its therapies could propel significant growth.

Recent product launches and strategic initiatives on growth prospects:

Currently, APLT lacks product launches but actively pursues strategic partnerships and licensing agreements to advance its pipeline development and accelerate potential commercialization.

Market Dynamics:

Overview of the industry APLT operates in:

The gene therapy and cell therapy market is rapidly growing, driven by technological advancements and promising therapeutic potential for various diseases. This market offers significant opportunities for APLT due to the high unmet medical needs and demand for innovative treatment solutions.

Analysis of how APLT is positioned within the industry:

APLT's competitive advantage lies in its novel gene therapy and cell therapy platforms, targeting rare diseases with limited treatment options. However, numerous competitors exist in this field, requiring APLT to demonstrate the efficacy and safety of its therapeutic candidates to gain market share.

Competitors:

Key competitors (including stock symbols):

  • BioMarin Pharmaceutical Inc. (BMRN)
  • uniQure N.V. (QURE)
  • Voyager Therapeutics, Inc. (VYGR)
  • Intellia Therapeutics, Inc. (NTLA)
  • Editas Medicine, Inc. (EDIT)

Market share percentages and comparison with APLT:

Market share comparisons are currently not available due to APLT's lack of marketed products.

Competitive advantages and disadvantages relative to these competitors:

APLT's advantages include its proprietary gene therapy and cell therapy platforms and its focus on rare diseases with limited treatment options. However, its competitors hold established market positions and larger financial resources.

Potential Challenges and Opportunities:

Key Challenges:

  • Successfully completing clinical trials and obtaining regulatory approvals for its lead candidates.
  • Demonstrating the long-term efficacy and safety of its gene therapy and cell therapy products.
  • Building a commercial infrastructure and establishing market access for its therapies.
  • Facing competition from established pharmaceutical companies and emerging biotechnology players.

Potential Opportunities:

  • Obtaining positive clinical trial results and securing regulatory approvals for its lead candidates.
  • Building strategic partnerships for further development and commercialization of its pipeline.
  • Expanding its product portfolio into new therapeutic areas with high unmet medical needs.
  • Leveraging technological advancements to enhance its gene therapy and cell therapy platforms.

Recent Acquisitions (last 3 years):

APLT has not completed any acquisitions in the last three years.

AI-Based Fundamental Rating:

As an AI, I cannot provide a personalized rating or financial advice. It is crucial to conduct thorough research and consult with a qualified financial advisor before making any investment decisions.

Sources and Disclaimers:

Disclaimer: This information is provided for general knowledge and educational purposes only. It does not constitute investment advice and should not be used as the sole basis for investment decisions. Always consult with a qualified financial professional before making any investment.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Applied Therapeutics Inc

Exchange NASDAQ Headquaters New York, NY, United States
IPO Launch date 2019-05-14 Chair of the Board of Directors, Founder, President, CEO & Secretary Dr. Shoshana Shendelman Ph.D.
Sector Healthcare Website https://www.appliedtherapeutics.com
Industry Biotechnology Full time employees 31
Headquaters New York, NY, United States
Chair of the Board of Directors, Founder, President, CEO & Secretary Dr. Shoshana Shendelman Ph.D.
Website https://www.appliedtherapeutics.com
Website https://www.appliedtherapeutics.com
Full time employees 31

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​